J.H. Whitney Equity Partners VII, LLC sold $7.4M of AVAH (indirect holdings)

J.H. Whitney Equity Partners VII, LLC sold 919,389 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $8.00 ($7.36M total) on 2026-06-24.

Original reporting
SEC EDGAR · J.H. Whitney Equity Partners VII, LLC
Published Jun 26, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Neutral
medium confidence
Mentioned
$AVAH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale: 919,389 shares for ~$7.36M at $8.00/share on 2026-06-24, reported by a 10% owner via indirect holdings.

02

Market read

Traders may briefly reassess sentiment around AVAH due to the disclosed owner selling, but there is no new guidance, earnings, or regulatory development.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which may lead traders to over-interpret intent; also, the post-sale share count remains substantial, so the sale may not imply a full exit.

Relevance 6/10Novelty 5/10Timing: filed 2026-06-26 after-hours/late session; transaction dated 2026-06-24

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Aveanna Healthcare Holdings, Inc. (AVAH).

Company-level read

Ticker impact

$AVAHNeutralMedium confidence
Context

Aveanna Healthcare Holdings disclosed a 10% owner indirect open-market sale of 919,389 shares at $8.00 on 2026-06-24 via Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

Form 4 provides a concrete transaction (size, price, date) but no new operating, regulatory, or guidance information. The filing also states no pre-arranged 10b5-1 plan, which can increase scrutiny, yet it remains a single sale disclosure.

Market effects

Minimal; this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A large indirect sale by a 10% owner can be routine liquidity/portfolio rebalancing rather than a bearish signal, especially without any accompanying negative company news.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Subject of the Form 4 insider transaction; ticker AVAH.

  • J.H. Whitney Equity Partners VII, LLC

    Reporter of the indirect open-market sale transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.